A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
A phase 1/2 trial of Blinatumomab in acute lymphoblastic leukaemia, run by Amgen, active and no longer recruiting.
Overview
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia is a phase 1/2 interventional study registered as NCT07134088 by Amgen, with 104 participants enrolled, started 2025-12-08 and due to reach its primary completion in 2028-12-05. Interventions recorded: Blinatumomab.
Similar pages
not linked directly; found by shared links- TrialA Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Shares Blinatumomab, BeOne Medicines (formerly BeiGene), Amgen, Acute lymphoblastic leukaemia and the tag pipeline.
- TrialClinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialA Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialCAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialStudy of YK012 in B-cell Acute Lymphoblastic Leukemia
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialTislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
Shares BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shares BeOne Medicines (formerly BeiGene) and the tag pipeline.
- TrialSafety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Shares Blinatumomab, Acute lymphoblastic leukaemia and the tag pipeline.